Lee Aven, Arachchige Buddhika Jayakody, Henderson Robert, Aylward James, McCombe Pamela Ann
Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.
Mass Spectrometry Facility, Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.
Neurodegener Dis. 2020;20(5-6):200-206. doi: 10.1159/000517964. Epub 2021 Jun 21.
Excitotoxicity is thought to be involved in the pathogenesis of amyotrophic lateral sclerosis (ALS). One possible source of excitotoxicity is the presence of sulphur amino acids (SAAs). In the brain of subjects with ALS, there are increased levels of taurine. In the metabolism of methionine to taurine, excitatory sulphur amino acids (SAAs) are formed. These could potentially contribute to excitotoxicity in ALS. The present study has examined whether plasma levels of SAAs in 38 ALS patients differ from those of 30 healthy controls.
Plasma levels of SAAs were measured by liquid chromatography mass spectrometry.
There were no significant changes in plasma cysteic acid, cysteine sulfinic acid, and homocysteic acid in ALS patients compared to healthy subjects. Significant elevations in plasma homocysteinesulfinic acid (HCSA) levels (p < 0.0001) were observed in the ALS patients (75.91 ± 15.38 nM) compared to healthy controls (54.06 ± 8.503 nM); 50% of the ALS patients had HCSA levels that were 1.5-2-folds higher than those of controls. Plasma levels of HCSA differed significantly (p = 0.0440) between patients with bulbar onset and spinal onset (68.57 ± 14.20 vs. 79.30 ± 14.95 nM, respectively).
HCSA is elevated in the blood of subjects with ALS. Since HCSA can be transported from the blood to the CNS by active transport, has neurotransmitter properties, and can activate synaptic receptors including NMDAR and metabotropic glutamate receptor, it is possible that increases in HCSA could influence glutamatergic neurotransmission and potentially contribute to excitotoxicity in some ALS patients.
兴奋性毒性被认为与肌萎缩侧索硬化症(ALS)的发病机制有关。兴奋性毒性的一个可能来源是含硫氨基酸(SAA)的存在。在ALS患者的大脑中,牛磺酸水平升高。在蛋氨酸代谢为牛磺酸的过程中,会形成兴奋性含硫氨基酸(SAA)。这些可能会导致ALS中的兴奋性毒性。本研究调查了38例ALS患者的血浆SAA水平是否与30例健康对照者不同。
采用液相色谱质谱法测定血浆SAA水平。
与健康受试者相比,ALS患者血浆中的半胱磺酸、半胱亚磺酸和高半胱氨酸水平无显著变化。与健康对照组(54.06±8.503 nM)相比,ALS患者血浆中的高半胱亚磺酸(HCSA)水平显著升高(p<0.0001)(75.91±15.38 nM);50%的ALS患者的HCSA水平比对照组高1.5至2倍。延髓起病和脊髓起病的患者血浆HCSA水平有显著差异(p = 0.0440)(分别为68.57±14.20和79.30±14.95 nM)。
ALS患者血液中的HCSA升高。由于HCSA可通过主动转运从血液进入中枢神经系统,具有神经递质特性,并可激活包括NMDAR和代谢型谷氨酸受体在内的突触受体,因此HCSA的增加可能会影响谷氨酸能神经传递,并可能导致部分ALS患者的兴奋性毒性。